Immunome Advances Varegacestat Toward FDA Approval with Strong Phase 3 Data — Immunome, Inc.

Event summary

Immunome's varegacestat met primary endpoint in Phase 3 RINGSIDE trial, showing 84% reduction in disease progression risk vs. placebo.
FDA accepted Immunome’s NDA for varegacestat with a PDUFA target action date of April 28, 2027.
Immunome reported $520 million in cash reserves as of June 30, 2026, expected to fund operations into 2028.
Three additional clinical-stage programs (IM-1021, IM-1617, IM-3050) are now enrolling patients.

The big picture

Immunome's progress with varegacestat positions it as a key player in the targeted oncology space, particularly for desmoid tumors. The strong Phase 3 data and FDA acceptance of the NDA highlight the company's ability to develop first-in-class therapies. With multiple clinical-stage programs in development, Immunome is poised to capitalize on the growing demand for innovative cancer treatments.

What we're watching

Regulatory Milestones: Whether the FDA approval process for varegacestat will proceed smoothly and meet the April 28, 2027 target date.
Pipeline Momentum: The pace at which Immunome can advance its additional clinical-stage programs (IM-1021, IM-1617, IM-3050) through trials and toward potential approvals.
Financial Sustainability: How Immunome will manage its cash reserves to support operations into 2028 while advancing multiple pipeline programs.